|
|
|
|
|
News and Articles on Actiq
Instanyl sets new standard in management of breakthrough cancer pain Sep 11, 2009
A multinational, open-label, crossover trial comparing Instanyl and Actiq for breakthrough cancer pain in patients receiving chronic opioid treatment. The trial investigated the efficacy of Instanyl compared to Actiq as well as ease of administration and patient preference ... 90% of patients found Instanyl was 'easy' or 'very easy' to use versus 40% for Actiq. (EurekAlert!)
Cephalon completes Arana purchase Aug 11, 2009
-Cephalon (NASDAQ:CEPH), whose products include the sleep disorder drug Nuvigil and the pain lozenge Actiq. We are excited about the advanced biological and molecular technology expertise that Arana brings to Cephalon, said Frank Baldino, the company s chairman and CEO. With biologics in inflammatory diseases and clinical candidates in oncology for solid tumors, this acquisition will catalyze the entry of Cephalon into the biologics space. (Philadelphia Business Journal, PA)
Cephalon earnings fall 72% on charge Feb 14, 2009
Pain drug sales were off slightly because of generic competition for cancer pain drug Actiq, the company said. Reader Comments. (Philadelphia Business Journal, PA)
[ Terms Of Use | Privacy | About ]
©1998-2009 SurfWax, Inc.
All rights reserved. Patents pending.
|
|
|
Copyright SurfWax, Inc. 2009
|
|
